Quantum BioPharma Ltd. Total Liabilities
Quantum BioPharma Ltd. total liabilities. Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) has total liabilities worth $8.29 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check QNTM asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Quantum BioPharma Ltd. (2015–2025)
Total liabilities of Quantum BioPharma Ltd. from 2015 to 2025. This chart illustrates how Quantum BioPharma Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore QNTM strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Quantum BioPharma Ltd. Competitors by Total Liabilities
The table below lists competitors of Quantum BioPharma Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Domo Activos Socimi SA
MC:DOMO
|
Spain | €215.90K |
|
Honkarakenne Oyj B
HE:HONBS
|
Finland | €12.30 Million |
|
DCM Limited
NSE:DCM
|
India | Rs826.30 Million |
|
Alliance Nickel Ltd
AU:AXN
|
Australia | AU$5.84 Million |
|
4Imprint Group Plc
LSE:FOUR
|
UK | GBX120.30 Million |
|
Millennium Group International Holdings Limited Ordinary Shares
NASDAQ:MGIH
|
USA | $10.85 Million |
|
Quartz Mountain Resources Ltd
V:QZM
|
Canada | CA$78.81K |
|
Polwax SA
WAR:PWX
|
Poland | zł55.33 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Quantum BioPharma Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see QNTM total asset value.
Liquidity & Leverage Metrics
Quantum BioPharma Ltd. Total Liabilities Ratios Explained
Quantum BioPharma Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quantum BioPharma Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quantum BioPharma Ltd. (2015–2025)
The table below shows the annual total liabilities of Quantum BioPharma Ltd. from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.05 Million | -9.46% |
| 2024-12-31 | $6.68 Million | +46.29% |
| 2023-12-31 | $4.57 Million | -41.98% |
| 2022-12-31 | $7.87 Million | -10.91% |
| 2021-12-31 | $8.83 Million | +56.08% |
| 2020-12-31 | $5.66 Million | -18.47% |
| 2019-12-31 | $6.94 Million | +442.08% |
| 2018-12-31 | $1.28 Million | +27.17% |
| 2017-12-31 | $1.01 Million | +1538.76% |
| 2016-12-31 | $61.43K | +1.49% |
| 2015-12-31 | $60.53K | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more